• Sep. 10, 2018 (PDF/210KB)R&D

  Results of Phase 3 Studies Evaluating Patch Formulation of Atypical Antipsychotic LONASEN Presented at Congress

• Sep. 03, 2018 (PDF/129KB)Corporate

  Sumitomo Dainippon Pharma announces personnel changes

• Sep. 01, 2018 (PDF/228KB)R&D

  FDA Issues a Complete Response Letter for New Drug Application for Dasotraline for the Treatment of ADHD

• Jul. 31, 2018 (PDF/107KB)R&D

  New Drug Application in Japan for Transdermal Patch Formulation of Atypical Antipsychotic LONASEN

• Jul. 30, 2018 (PDF/84KB)R&D

  Kyoto University Hospital and the Center for iPS Cell Research and Application (CiRA) to begin Physician-initiated Clinical Trials for Parkinson's Disease that Transplants Dopamine progenitor cells generated from Induced Pluripotent Stem (iPS) Cells

more